| ²é¿´: 1335 | »Ø¸´: 1 | |||
[½»Á÷]
ÀîºìÁ¼½ÌÊÚ¡¶È¥·ºËØ»¯Ã¸TNFAIP3ͨ¹ýÒÖÖÆ¸ÎÔàASK1»îÐÔ»º½â·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎÑס·
|
|
¹úÊÇÊÀ½ç¸Î²¡´ó¹ú£¬È«¹ú³¬¹ý3ÒÚÈË´æÔÚ²»Í¬³Ì¶ÈµÄ·Ç¾Æ¾«ÐÔÖ¬·¾¸Î£¬¿É½øÒ»²½·¢Õ¹Îª¸ÎÓ²»¯£¬ÉõÖÁ¸Î°©¡¢¸ÎË¥½ß£¬Í¬Ê±Ôö¼Ó¶àÖÖÐÄÄÔѪ¹ÜºÍ´úлÐÔ¼²²¡»¼²¡·çÏÕ¡£È»¶ø£¬¹ú¼ÊÉÏÉÐÎÞÕë¶Ô·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎµÄÁÙ´²ÓÃÒ©¡£¸ÎÔàÇгýºÍ¸ÎÔàÒÆÖ²³ÉΪÖÎÁÆÍíÆÚ¸Î²¡µÄÖ÷ÒªÊֶΣ¬µ«ÊÖÊõ¹ý³ÌÖв»¿É±ÜÃâµÄ¸ÎÔàȱѪÔÙ¹à×¢ËðÉ˼«´óÏÞÖÆÁ˸ÎÔàÊÖÊõµÄ¿ªÕ¹ºÍ¾ÈÖÎЧ¹û¡£ ±¾´Î·¢±íµÄÁ½ÆªÂÛÎÄÖУ¬¡°The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis¡±£¨¡¶È¥·ºËØ»¯Ã¸TNFAIP3ͨ¹ýÒÖÖÆ¸ÎÔàASK1»îÐÔ»º½â·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎÑס·£©²ûÊÍÁËÒ»ÌõеķǾƾ«ÐÔÖ¬·¾¸Î²¡·¢Õ¹ÄÚÔÚµÄÒÖÖÆÍ¾¾¶¡£²©Ê¿ºóÕÅÅô¡¢ÍõاÏþ¡¢²©Ê¿ÉúÕÔÁáÆ¼Îª¹²Í¬µÚÒ»×÷Õߣ¬ÀîºìÁ¼ºÍÕÛÖ¾¸Õ½ÌÊÚΪ¹²Í¬Í¨Ñ¶×÷Õß¡££¨ÂÛÎÄÁ´½Ó£ºhttps://www.nature.com/articles/nm.4453£© Activation of apoptosis signal-regulating kinase 1 (ASK1) in hepatocytes is a key process in the progression of nonalcoholic steatohepatitis (NASH) and a promising target for treatment of the condition. However, the mechanism underlying ASK1 activation is still unclear, and thus the endogenous regulators of this kinase remain open to be exploited as potential therapeutic targets. In screening for proteins that interact with ASK1 in the context of NASH, we identified the deubiquitinase tumor necrosis factor alpha¨Cinduced protein 3 (TNFAIP3) as a key endogenous suppressor of ASK1 activation, and we found that TNFAIP3 directly interacts with and deubiquitinates ASK1 in hepatocytes. Hepatocyte-specific ablation of Tnfaip3 exacerbated nonalcoholic fatty liver disease¨C and NASH-related phenotypes in mice, including glucose metabolism disorders, lipid accumulation and enhanced inflammation, in an ASK1-dependent manner. In contrast, transgenic or adeno-associated virus¨Cmediated TNFAIP3 gene delivery in the liver in both mouse and nonhuman primate models of NASH substantially blocked the onset and progression of the disease. These results implicate TNFAIP3 as a functionally important endogenous suppressor of ASK1 hyperactivation in the pathogenesis of NASH and identify it as a potential new molecular target for NASH therapy. |
» ²ÂÄãϲ»¶
½ñÌì¿ÉÄܹ«²¼Âð
ÒѾÓÐ3È˻ظ´
½ñÌìÀí½âÐÒ´æÕ߯«²îµÄº¬Òå¡£
ÒѾÓÐ6È˻ظ´
ÖÐҩѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ239È˻ظ´
д¸øÊ§ÒâÖеijæÓѺÍʧÒâ¹ýµÄÈË
ÒѾÓÐ27È˻ظ´
NCÒ»¸ö
ÒѾÓÐ10È˻ظ´
ÁÙ´²Ò½Ñ§³õÊÔ306£¬Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
ÆÚ¿¯ÒÔÎ÷°àÑÀÓïÓ¡Ë¢£¬Ò»¶¨ÒªÓÃÎ÷°àÑÀÓïд¸åͶ¸åÂð£¿
ÒѾÓÐ0È˻ظ´
skin research and technologyÖ§¸¶APCºó1¸öÔÂÁË£¬»¹ÔÚÖÆ×÷ÖÐ
ÒѾÓÐ5È˻ظ´
¿¼Ñе÷¼Á
ÒѾÓÐ4È˻ظ´
|
The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis Peng Zhang, Pi-Xiao Wang, Ling-Ping Zhao, Xin Zhang, Yan-Xiao Ji, Xiao-Jing Zhang, Chun Fang, Yue-Xin Lu, Xia Yang, Mao-Mao Gao, Yan Zhang, Song Tian, Xue-Yong Zhu, Jun Gong, Xin-Liang Ma, Feng Li, Zhihua Wang, Zan Huang, Zhi-Gang She & Hongliang Li |
2Â¥2018-07-17 21:51:27













»Ø¸´´ËÂ¥